assay development Latest News

Cholesterol removal from serum samples using Cleanascite™ for immunogenicity and safety endpoint analysis of pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine.

The BBI Group is determined to steal the show at this year’s American Association for Clinical Chemistry event with the launch of its new hand held reader and end to end IVD assay development solution.

Cambridge Healthtech Institute (CHI) is pleased to offer this pre-conference short course on Tuesday, November 15 at the DoubleTree Hotel in Bethesda, MD.

A 2-part event covering developments in assay technologies, risk assessment, regulatory guidance and means of predicting and avoiding immunogenicity. Early registration discounts will be offered until August 26.

tebu-bio is pleased to be participating at the ELA Screening Europe conference which will take place in Hamburg from June 30th to July 1st, 2011

This conference will also provide a venue for professionals in the drug discovery industry and academics to get an update of exciting new developments in assay technologies and exchange ideas in developing creative approaches in the drug discovery

ECI Biotech of Worcester, MA, a premier developer of low cost and rapid diagnostics trademarked as ExpressDetect, has received a $511K Phase II Grant to develop a hand-held diagnostic tool for point-of-care detection of infection in chronic wounds.

GenScript expands its drug discovery services to assay development.

The presentation highlighted ECI Biotech’s patented ExpressDetect Diagnostic technology that enables rapid, easy detection of microbial pathogens. Target markets include: feminine care, wound care, oral care, and hospital infection control.

Dr. Taosheng Chen, Director of HTS, St. Jude Children's Research Hospital will present at GTCbio’s 3rd Assay Development & Screening Technologies Conference on June 5-6, 2008 in San Francisco, CA.

Dr. Xi Chen, Assistant Professor in the Department of Chemistry at the University of California, Davis will present at GTCbio’s 3rd Assay Development & Screening Technologies Conference on June 5-6, 2008 in San Francisco, CA

Dr. John W. Cuozzo, Director of ELT Lead Discovery at GlaxoSmithKline will present at GTCbio’s 3rd Assay Development & Screening Technologies Conference on June 5-6, 2008 in San Francisco, CA.

Hakim Djaballah, Director of HTS at Memorial Sloan Kettering Cancer Center to Present at GTCbio’s 3rd Assay Development & Screening Technologies Conference, June 5-6, 2008 in San Francisco, CA